actinium-225

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

ATNM-400 from Actinium Pharmaceuticals (ATNM) shows breakthrough promise in resistant breast cancer

Actinium’s ATNM-400 shows potent activity in resistant breast cancer and TNBC. Find out what the new SABCS 2025 data reveal about this radiopharma candidate.

byVenkatesh

December 1, 2025

AtomVie Global Radiopharma partnering with TerraPower Isotopes to secure actinium-225 for global cancer therapy development

AtomVie Global Radiopharma signs agreement with TerraPower Isotopes to secure actinium-225 supply, aiming to advance CDMO-based cancer radiotherapies.

bySoujanya Ravi

June 18, 2025

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

ATNM-400 from Actinium Pharmaceuticals (ATNM) shows breakthrough promise in resistant breast cancer

AtomVie Global Radiopharma partnering with TerraPower Isotopes to secure actinium-225 for global cancer therapy development

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue

Sumitomo Forestry expands U.S. housing footprint with $4.5bn Tri Pointe Homes acquisition

Applied Optoelectronics Inc. Texas expansion marks next phase in optical components reshoring push

What Patrick Dumont’s rise to CEO reveals about Las Vegas Sands Corp.’s post-founder strategy